College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, 52 Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Republic of Korea.
Sci Rep. 2021 May 11;11(1):10037. doi: 10.1038/s41598-021-89490-z.
Although a considerable volume of data supporting induction or aggravation of psoriasis because of angiotensin-converting enzyme (ACE) inhibitor use exists, it remains insufficient for definitive conclusions. Therefore, we aimed to evaluate the association between ACE inhibitor use and psoriasis incidence through a systematic literature review and meta-analysis. We searched for qualifying studies across PubMed, Web of Science, and Embase. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the strength of the association between ACE inhibitor use and psoriasis incidence. Eight studies with a total of 54,509 patients with a psoriasis diagnosis were included in this meta-analysis. The pooled OR for psoriasis incidence among ACE inhibitor users was 1.52 (95% CI, 1.16-2.00) compared to that among non-users. From subgroup analysis by continent, the OR for ACE inhibitor users versus non-users was 2.37 (95% CI 1.28-4.37) in Asia. Per the subgroup analysis by climate, the OR for ACE inhibitor users vs non-users in dry climate was 3.45 (95% CI: 2.05-5.79) vs 1.32 (95% CI 1.01-1.73) in temperate climate. Our results reveal a significant association between ACE inhibitor use and psoriasis incidence.
尽管有相当数量的数据支持血管紧张素转换酶（ACE）抑制剂的使用会导致或加重银屑病，但这些数据仍不足以得出明确的结论。因此，我们旨在通过系统的文献回顾和荟萃分析来评估 ACE 抑制剂的使用与银屑病发病之间的关联。我们在 PubMed、Web of Science 和 Embase 中搜索了符合条件的研究。计算了比值比（OR）和 95%置信区间（CI），以评估 ACE 抑制剂的使用与银屑病发病之间的关联强度。这项荟萃分析共纳入了 8 项研究，总计 54509 例银屑病患者。与非使用者相比，ACE 抑制剂使用者中银屑病的发生率的合并 OR 为 1.52（95%CI，1.16-2.00）。按大陆进行亚组分析，亚洲 ACE 抑制剂使用者与非使用者的 OR 为 2.37（95%CI 1.28-4.37）。按气候进行亚组分析，在干燥气候中，ACE 抑制剂使用者与非使用者的 OR 为 3.45（95%CI：2.05-5.79），而在温带气候中，OR 为 1.32（95%CI 1.01-1.73）。我们的结果表明 ACE 抑制剂的使用与银屑病的发病之间存在显著关联。
